You are here

Press Release Archive

 
- Pfizer Invites Public to View and Listen to Webcast of February 1 Conference Call with Analysts

(BUSINESS WIRE)--Pfizer Inc. invites investors and the general public to view and listen to a webcast of a conference call with investment analysts at 10 a.m. EST on Tuesday, February 1, 2011. The purpose of the call is to provide an update on Pfizer’s results, as reflected in the company’s Fourth Quarter 2010 Performance Report, to be issued that morning. To view and listen to the webcast and view the Performance Report, visit our

 
- Pfizer Invites Public to View and Listen to Webcast of Pfizer Presentation at Healthcare Conference

(BUSINESS WIRE)--Pfizer Inc. invites investors and the general public to view and listen to a webcast of a presentation by Geno Germano, President and General Manager, Specialty Care and Oncology, at the 29th Annual J.P. Morgan Healthcare Conference on Tuesday, January 11, 2011 at 3:00 p.m. Pacific Standard Time. To view and listen to the webcast, visit our web site at www.pfizer.com and click on the “29th Annual J.P. Morgan

 
- Pfizer Animal Health Completes Acquisition of Synbiotics Corporation

(BUSINESS WIRE)--Pfizer Animal Health today announced the completion of its acquisition of Synbiotics Corporation (Pinksheets SYNB.PK) on December 30, 2010, resulting in the cessation of trading of Synbiotics common stock.

Shareholders of record of Synbiotics’ common stock will receive written instructions, including a letter of transmittal, for exchanging their Synbiotics common stock for the merger consideration. Holders in "street" name should contact their broker to receive their merger consideration. It is estimated that Synbiotics common shareholders will be entitled to receive up to approximately $0.306 per share in cash in connection with the acquisition, of which approximately $0.019 per share will be held in escrow as a fund against which Pfizer may make claims for any losses arising from any breaches of Synbiotics' representations, warranties, covenants and agreements and similar customary matters

 
- Pfizer Extends Tender Offer To Acquire King Pharmaceuticals, Inc.

(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE) today announced that its wholly-owned subsidiary, Parker Tennessee Corp., has extended the expiration date of its tender offer for all outstanding shares of common stock of King Pharmaceuticals, Inc. (NYSE: KG) for $14.25 per share, net to the seller in cash, without interest thereon and subject to any required withholding taxes. The tender offer is now scheduled to expire at 12:00 midnight, New York

 
- Pfizer Declares A 20-Cent First-Quarter 2011 Dividend

(BUSINESS WIRE)--The board of directors of Pfizer Inc. (NYSE: PFE) today declared a 20-cent first-quarter 2011 dividend on the company's common stock, payable March 1, 2011, to shareholders of record at the close of business on February 4, 2011. Pfizer increased the dividend by approximately 11 percent, to 20 cents from 18 cents per share. "This dividend increase is a testament to our commitment to enhance shareholder value and

 
- Pfizer Board of Directors Elects George A. Lorch Non-Executive Chairman

(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE) announced today that the Company's Board of Directors has elected George A. Lorch, 68, who has served as an independent director since 2000, as non-executive Chairman of the Board, effective immediately. The Board's Lead Independent Director, Constance J. Horner, said, "George Lorch has been a valuable, independent voice on the Pfizer Board for over 10 years, and he is ideally suited to lead

 
- Young Children In Developing World Receive Accelerated Access to Pfizer's Prevenar 13 Vaccine

(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE) announced that Prevenar 13* (Pneumococcal polysaccharide conjugate vaccine [13-valent, adsorbed]) was introduced into the first childhood immunization program for pneumococcal disease (PD) in the developing world under the auspices of the Advance Market Commitment (AMC) when Nicaragua launched its program today. The AMC is an innovative program which involves private-public partnerships to help make

 
- Pfizer Stops Clinical Trials of Thelin® and Initiates Voluntary Product Withdrawal in the Interest of Patient Safety

(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE) announced today that, in the interest of patient safety, it is voluntarily withdrawing Thelin® (sitaxentan) for the treatment of pulmonary arterial hypertension (PAH) in regions where it is approved (the European Union, Canada and Australia). In addition, Pfizer is discontinuing clinical studies of Thelin worldwide. Pfizer's decision was based on a review of emerging safety information from

 
- Angie Harmon and Children's Advil® Invite Families to Sing Away the Cold and Flu Season Blues

MADISON, N.J.--(BUSINESS WIRE)--At the height of this year's cold and flu season, Angie Harmon, mom of three, is teaming up with the makers of Children's Advil® to launch "Relieve My Fever" -- a contest that invites parents and their kids to sing the Children's Advil® rendition of the classic song "Fever" for a chance to win $15,000. The kid-friendly version of the song tells the story of mommy fighting her little one's fever and making her child feel

 
- National Initiative Urges 10 Million At-Risk Boomers to 'Face Alzheimer's'

CHICAGO and NEW YORK--(BUSINESS WIRE)--With as many as 10 million U.S. baby boomers at risk for developing Alzheimer's,(1) the Alzheimer's Association and Pfizer (NYSE: PFE) are collaborating to help raise awareness of Alzheimer's disease by emphasizing to all Americans, "It's Time to Face Alzheimer's." The effort encourages people to share photos and stories related to their personal experience with the disease in an effort to show the real and varied

 
- Pfizer Announces Phase 3 Results of Investigational Compound Bosutinib in Patients With Newly Diagnosed Chronic Myeloid Leukemia

(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE) announced today that a significantly higher proportion of patients with newly diagnosed chronic myeloid leukemia who were treated with bosutinib (39 percent) experienced a major molecular response (MMR), a secondary endpoint, compared with patients treated with imatinib (26 percent) in the intent-to-treat (ITT) population (p=0.002). However, the study did not meet its primary endpoint of superior

 
- Pfizer Board of Directors Names Ian C. Read President and Chief Executive Officer

(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE) today announced that its Board of Directors has elected Ian C. Read, 57, currently head of the Company's global biopharmaceutical operations, as President, Chief Executive Officer and Director. Mr. Read succeeds Jeffrey B. Kindler, who has retired from the Company. The Board's Lead Independent Director, Constance J. Horner, said, "In 2006, Jeff Kindler took on the challenge of transforming

 
- Pfizer Plans Regulatory Submissions of Bosutinib in Chronic Myeloid Leukemia

(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE) announced today it is planning regulatory submissions of bosutinib in patients with chronic myeloid leukemia (CML) based on data from a clinical program evaluating the compound in newly diagnosed and previously treated patients. These regulatory submissions are planned for 2011. Pfizer has begun the process of preparing a Marketing Authorization Application (MAA) for submission to the European

 
- AVERROES Study of Investigational Agent Apixaban Closes Early Due to Clear Evidence of Efficacy

PRINCETON, N.J. and NEW YORK--(BUSINESS WIRE)--Bristol-Myers Squibb Company (NYSE: BMY) and Pfizer (NYSE: PFE) today announced that the companies have agreed to stop the Phase 3 AVERROES clinical trial of apixaban in patients with atrial fibrillation. The study will be stopped early because a predefined interim analysis by the independent Data Monitoring Committee (DMC) revealed clear evidence of a clinically important reduction in stroke and

 
- Centrum® and Molly Shannon Search for 'America's Most Amazingly Energized Woman' This Holiday Season

MADISON, N.J.--(BUSINESS WIRE)--Getting it all done while enjoying life takes the right attitude and energy. A new contest from the makers of Centrum® multivitamins seeks to find out how some women manage to stay energized to enjoy life and love to the max this holiday season. Despite a calendar full of parties to plan and gifts to wrap, there are always those special women who manage to get everything done with a smile on their face, and the makers of

 
- SUTENT® Receives European Approval for a New Indication in Progressive Pancreatic Neuroendocrine Tumors (NET)

(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE) announced today that the European Commission has approved SUTENT® (sunitinib malate) for the treatment of unresectable or metastatic, well-differentiated pancreatic neuroendocrine tumors (NET) with disease progression in adults. Experience with SUTENT as initial treatment is limited in this disease. Pancreatic NET is a rare cancer reported in two to four people per million annually worldwide.(1,2)

 
- Caltrate® Soft Chews Offer A New and Delicious Way to Help Americans Reach Their Recommended Daily Calcium and Vitamin D Intake

MADISON, N.J.--(BUSINESS WIRE)--On the heels of the Institute of Medicine increasing the daily recommended intake of vitamin D to maintain bone health, Americans may be left wondering how to meet the new guidelines. Pfizer Consumer Healthcare, the makers of the #1 selling brand of calcium and vitamin D supplements, announces the launch of new Caltrate® Soft Chews, a great-tasting and convenient way to help reach the new, higher daily vitamin D goals

 
- Pfizer to Present Data from Its Hematology Portfolio at the 52nd Annual Meeting of the American Society of Hematology

(BUSINESS WIRE)--Pfizer (NYSE: PFE) said today that new data on investigational compounds in its hematology portfolio will be presented at the 52nd Annual Meeting of the American Society of Hematology (ASH) in Orlando, December 4-7. Key highlights include results from a Phase 3 study, called the BELA (Bosutinib Efficacy and safety in chronic myeloid LeukemiA) study, involving bosutinib for the treatment of newly diagnosed Philadelphia

 
- Pfizer and Protalix BioTherapeutics Announce Submission of taliglucerase alfa for European Marketing Authorization for the Treatment of Gaucher Disease

Pfizer Inc. (NYSE: PFE) and Protalix BioTherapeutics, Inc. (NYSE-Amex: PLX, TASE: PLX) today announced the submission of a Marketing Authorization Application to the European Medicines Agency for taliglucerase alfa, a plant-cell expressed form of glucocerebrosidase (GCD)for the treatment of Gaucher disease. Taliglucerase alfa was granted Orphan Designation by the European Commission for the treatment o

 
- Pfizer Extends Tender Offer to Acquire King Pharmaceuticals, Inc.
 
(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE) today announced that its wholly-owned subsidiary, Parker Tennessee Corp., has extended the expiration date of its tender offer for all outstanding shares of common stock of King Pharmaceuticals, Inc. (NYSE: KG) for $14.25 per share, net to the seller in cash, without interest thereon and subject to any required withholding taxes. The tender offer is now scheduled to expire at 12:00 midnight, New York

Pages

Note: These press releases were issued in the United States and are intended as reference information for U.S. investors and journalists. The information contained in each press release was accurate at the time of issuance, and Pfizer assumes no responsibility for updating the information to reflect subsequent developments.

 

Stock Quote Disclaimer

20 minute delayed data provided by Comstock. Charts are provided by BigCharts and MarketWatch, Inc. Pfizer makes no claims concerning the accuracy of the information provided on these pages, and will not be held liable for any use of this information. Note: Historical and current stock price performance data is not necessarily indicative of future performance.

pdf

If you do not have Adobe® Reader, download it here. It is available without charge from Adobe®. This link is provided as a convenience. Pfizer is not responsible for the content of this linked page.